<DOC>
	<DOCNO>NCT01340209</DOCNO>
	<brief_summary>The aim trial evaluate safety efficacy 2.5 5 µg tiotropium 52-week treatment period compare placebo . Tiotropium inhalation solution deliver Respimat inhaler examine top maintenance treatment inhale corticosteroid controller medication patient moderate severe persistent asthma . Efficacy safety assess measuring effect lung function , effect asthma exacerbation , effect asthma control , number adverse event .</brief_summary>
	<brief_title>Evaluation Tiotropium 2.5 5 µg Once Daily Delivered Via Respimat Inhaler Compared Placebo Patient With Moderate Severe Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient include patient age ( 20 year old ) must sign date Informed Consent Form consistent ICHGCP guideline Good Clinical Practice ( GCP ) prior participation trial [ i.e . prior trial procedure , include pretrial washout medication medication restriction pulmonary function test ( PFT ) Visit 1 ] . Regarding patient age , guardian legally authorised representative must also sign date Informed Consent Form . 2 . Male female outpatient age least 18 year 75 year Visit 0 . 3 . All patient must least 12week history asthma time enrolment ( Visit 0 ) trial . The diagnosis confirm Visit 1 fulfil inclusion criterion 5 . 4 . The initial diagnosis asthma must make patient 's age 40 . 5 . The diagnosis asthma confirm Visit 1 bronchodilator reversibility ( 1530 minute 400 µg salbutamol ) result Forced Expiratory Volume one second ( FEV1 ) increase least 12 % least 200 mL . 6 . All patient must maintenance treatment medium , stable dose inhaled corticosteroid ( ICS ) [ alone fix combination Longacting betaadrenergic ( LABA ) ] least 4 week prior Visit 1 . 7 . All patient must symptomatic Visit 1 ( screen ) prior randomisation Visit 2 define Asthma Control Questionnaire ( ACQ ) mean score least 1.5 . 8 . All patient must prebronchodilator FEV1 least 60 % less equal 90 % predict normal Visit 1 . 9 . Patients must neversmokers exsmokers stop smoke least one year ( 52 week ) prior enrolment ( Visit 0 ) smoke history le 10 pack year . 10 . Patients must able use Respimat inhaler correctly , judge discretion investigator.. 11 . Patients must able perform trial related procedure include technically acceptable PFTs use electronic diary ( eDiary ) /peak flow meter , judge discretion investigator . Exclusion criterion : 1 . Patients significant disease asthma . A significant disease define disease , opinion investigator , may ( ) put patient risk participation trial , ( ii ) influence result trial , ( iii ) cause concern regard patient 's ability participate trial . 2 . Patients clinically relevant abnormal screening ( Visit 1 ) haematology blood chemistry abnormality define significant disease define exclusion criterion 1 . 3 . Patients recent history ( i.e . 6 month less ) myocardial infarction prior Visit 0 . 4 . Patients hospitalise cardiac failure past year prior Visit 0 . 5 . Patients unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year prior Visit 0 . 6 . Patients lung disease asthma ( e.g . COPD ) . 7 . Patients know active tuberculosis . 8 . Patients malignancy and/or patient undergone resection , radiation therapy chemotherapy malignancy within last 5 year prior Visit 0 . Patients treat basal cell carcinoma allow . 9 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion . 1 . 10 . Patients significant alcohol drug abuse , judge discretion investigator , within past 2 year prior Visit 0 . 11 . Patients know hypersensitivity anticholinergic drug , benzalkonium chloride ( BAC ) , ethylenediaminetetraacetic acid ( EDTA ) , component study medication delivery system . 12 . Pregnant nursing woman . 13 . Women childbearing potential use highly effective method birth control . 14 . Patients take investigational drug within 4 week prior Visit 1 . 15 . Patients treat betablocker medication within four week prior Visit 1 and/or screen period . Topical cardioselective betablocker eye medication nonnarrow angle glaucoma allow . 16 . Patients treat longacting anticholinergic tiotropium ( Spiriva ) within four week prior Visit 1 and/or screen period . 17 . Patients treat oral betaadrenergics within four week prior Visit 1 and/or Screening period . 18 . Patients treat systemic corticosteroid within four week prior Visit 1 and/or screen period . 19 . Patients treat antiIgE antibody , e.g . omalizumab ( Xolair® ) , within 6 month prior Visit 1 and/or screen period . 20 . Patients treat nonapproved accord international guideline recommend `` experimental '' drug routine asthma therapy within four week prior Visit 1 and/or screen period . 21 . Patients asthma exacerbation respiratory tract infection four week prior Visit 1 and/or screen period . 22 . Patients currently participate another trial . 23 . Patients narrowangle glaucoma and/or micturition disorder due prostatic hyperplasia . 24 . Patients 80 % eDiary completion compliance Visit 2 ( diary compliance least 80 % require ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>